Alfonso Cortes

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Histologic and Molecular Type Changes in Endometrial Cancer Recurrences in Comparison With Their Corresponding Primary Tumors.

Histologic and Molecular Type Changes in Endometrial Cancer Recurrences in Comparison With Their Corresponding Primary Tumors.

Journal: The American journal of surgical pathology

Published: September 13, 2024

Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study.

Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study.

Journal: Breast (Edinburgh, Scotland)

Published: July 29, 2024

Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients.

Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients.

Journal: The oncologist

Published: April 15, 2024

Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent.

Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent.

Journal: Cancer immunology, immunotherapy : CII

Published: March 24, 2024

Adoptive T cell therapy for solid tumors: current landscape and future challenges.

Adoptive T cell therapy for solid tumors: current landscape and future challenges.

Journal: Frontiers in immunology

Published: December 08, 2023

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.

Journal: Lancet (London, England)

Published: September 29, 2023

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature.

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature.

Journal: Frontiers in oncology

Published: February 04, 2023

Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors.

Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors.

Journal: Cancers

Published: December 30, 2022

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study.

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study.

Journal: Cancers

Published: November 08, 2022

Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study.

Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study.

Journal: BMC cancer

Published: June 22, 2022

Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era.

Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: June 07, 2022

Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases.

Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases.

Journal: Cancers

Published: February 04, 2022

Showing 1-12 of 21

Last Updated: 09/26/2026